Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Superconductor Corporation (AMSC) vs Zoetis Inc (ZTS) Price & Performance

American Superconductor Corporation
Zoetis Inc

Price performance

Price movement over the last 24 hours

Key statistics

American Superconductor Corporation vs Zoetis Inc — how do they compare? American Superconductor Corporation trades at $35.49 (market cap $1.74B), while Zoetis Inc trades at $75.97 (market cap $31.68B). The key difference: Zoetis Inc is far larger — about 18.2× American Superconductor Corporation's market cap, and Zoetis Inc pays a 2.81% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.

AMSCZTS
Market Cap
$1.74B$31.68B
Sector
TechnologyHealth
52-Week High
$66.68$156.76
52-Week Low
$25.95$71.91
Enterprise Value
$1.61B$38.97B
Dividend Yield
2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Superconductor Corporation

AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.

The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.

Zoetis Inc

Zoetis (ZTS) trades at $75.56, up 0.64% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 28.03% net margins and 67.75% ROE, supported by consistent revenue growth to $9.47B in 2025. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with a $101.43 price target. Legal developments include multiple securities class action notices with July 27, 2026 deadlines.

ZTS presents a mixed outlook with strong fundamental performance offset by technical weakness and legal overhangs. The stock trades at attractive valuations (P/E 12.39) with significant upside to analyst targets, but investors face near-term volatility from the class action proceedings and recent earnings miss. Long-term growth prospects remain solid given the company's market leadership in animal health.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Superconductor Corporation

AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.

Read more on AMSC

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS